Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444187 | PMC |
http://dx.doi.org/10.31744/einstein_journal/2022CE0018 | DOI Listing |
Expert Opin Biol Ther
January 2025
Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Introduction: Emerging evidence suggests that, while CD19 is primarily expressed on immature B-cell precursors, it is also present on drug-resistant plasma cells that have been postulated to function as multiple myeloma (MM) stem cells, driving the progression of relapsing disease. Targeting CD19 with chimeric antigen receptor (CAR) T cells offers a promising strategy for addressing this residual disease burden, potentially leading to more durable treatments and enhanced relapse prevention.
Areas Covered: This review examines the molecular basis of CD19-targeted CAR-T therapy in MM, highlighting its potential, key challenges, and efficacy and safety in early clinical trials for relapsed/refractory and newly diagnosed MM.
Hematology Am Soc Hematol Educ Program
December 2024
UT Southwestern Medical Center, BioCenter, Dallas, TX.
Classification of acute leukemia involves assigning lineage by resemblance of blasts to normal progenitor cells. This approach provides descriptive information that is useful for disease monitoring, provides clues to pathogenesis, and can help to select effective chemotherapeutic regimens. Acute leukemias of ambiguous lineage (ALAL) are those leukemias that either fail to show evidence of myeloid, B-lymphoid, or T-lymphoid lineage commitment or show evidence of commitment to more than 1 lineage, including mixed-phenotype acute leukemia (MPAL).
View Article and Find Full Text PDFPeerJ
November 2024
Neurosurgery Department, Jinzhou Central Hospital, Jinzhou, China.
Haematologica
October 2024
Department for Biological Sciences and Pathobiology, University of Veterinary Medicine, Vienna.
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of cancer research when looking for targeted therapies. We discovered cyclin C as a key factor for B-ALL development and maintenance.
View Article and Find Full Text PDFGenes Dev
October 2024
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!